Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-02-01
2009-06-09
Mosher, Mary E (Department: 1648)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S235100, C435S236000, C424S224100
Reexamination Certificate
active
07544791
ABSTRACT:
A mutant virus is provided which contains a mutation at a phosphorylation site in one or more of the proteins of the virus, which mutation causes the virus to be attenuated, and therefore, an improved vaccine composition can be produced therewith. The invention also relates to vaccine compositions which contain the mutant virus, as well as to methods of inducing an immune response, and of protecting mammals from infection by rabies virus. Also included in the invention are methods of producing the mutant virus and mutant viral proteins, including producing the mutant virus in a host cell which produces or even overproduces a wild-type counterpart of the mutant viral protein, which complements the other viral proteins such that production of the mutant viral particle is optimized. The invention also includes those host cells in which viral production is optimized, as well as vaccine compositions including the viral proteins, either alone or in combination with the intact virus, and to methods of inducing an immune response or protecting a mammal from infection, using the same. Also included in the invention are vectors suitable for delivering a gene to a cell of a human or animal, as well methods of delivery thereof.
REFERENCES:
patent: 4342566 (1982-08-01), Theofilopoulos et al.
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5583735 (1996-12-01), Pease et al.
patent: 6033886 (2000-03-01), Conzelmann
patent: 6706523 (2004-03-01), Fu
patent: 6719881 (2004-04-01), Hunter et al.
patent: 7419816 (2008-09-01), Fu
patent: 0583998 (1994-02-01), None
patent: 99/18214 (1999-04-01), None
patent: 00/32755 (2000-06-01), None
Wagner et al, in Fields Virology, Third edition, ed. Fields et al, Lippincott-Raven, Philadelphia, 1996, pp. 1121-1135.
Dietzchold et al (Expert Rev. Vaccines 2:399-406, 2003).
Morimoto et al (Vaccine 19: 3543-3551, 2001).
Schnell et al (Journal of Neurovirology 11:76-81, 2005).
A. Flamand et al., “An RNA polymerase activity in purified rabies virions”, J. Gen. Virol., 1978, pp. 233-238, vol. 40, Society for General Microbiology, United Kingdom.
A. Flamand et at., Avirulent mutants of rabies virus and their use as live vaccine, Trends. Microbiol., Nov. 1993, pp. 317-320, vol. 1, No. 8, Elsevier Science Publishers Ltd, Cambridge,U.K.
A. Kawai et al., “Nucleocapsid formation and/or subsequent conformational change of rabies virus nucleoprotein (N) is a prerequisite step for acquiring the phosphatase-sensitive epitope of monoclonal antibody 5-2-26”, Virology, 1999, pp. 395-407, vol. 263, Academic Press, San Diego, CA.
A. Kawai, “Transcriptase Activity Associated With Rabies Virion”, J. Virol., Dec. 1977, pp. 826-835, vol. 24, No. 3, American Society for Microbiology, Washington, DC.
A. Kouznetzoff et at., “Identification of a region of the rabies virus N protein involved in direct binding to the viral RNA”, J. Gen. Virol., 1998, pp. 1005-1013, vol. 79, Society of General Microbiology, United Kingdom.
A. Trejos et al., “Laboratory investigations of neuroparalytic accidents associated with suckling mouse brain rabies vaccine. I.—Encephalitogenicity and virological studies”, Ann. Immunol. (Paris—Inst. Pasteur), 1971, pp. 917-924, vol. 125.
A. Wandeler et al., “Oral Immunization of Wildlife Against Rabies: Concept and First Field Experiments”, Rev. Infect. Dis., Nov.-Dec. 1988, pp. S649-S653, vol. 10, Suppl. 4, The University of Chicago Press, Chicago, IL.
A.B. Sabin et al., “History of the Sabin attenuated po(iovirus oral live vaccine strains”, J. Biol. Stand., 1973, pp. 115-118, vol. 1, No. 2, Academic Press Inc., London, UK.
A.H. Robbins et al., “Prevention of the spread of rabies to wildlife by oral vaccination of raccoons in Massachusetts”, J. Am. Vet. Med. Assoc., Nov. 15, 1998, pp. 1407-1412, vol. 213, No. 10, Journalof the American Veterinary Medical Association, Schaumburg, IL.
A.K. Banerjee et at., “Structure and Function of the RNA Polymerase of Vesicular Stomatitis Virus”, Advances in Virus Research, 1990, pp. 99-124, vol. 38, Academic Press.
A.K. Pattnaik et al., “Cells that express all five proteins of vesicular stomatitis virus from cloned cDNAs support replication, assembly, and budding of defective interfering particles”, Proc. Natl. Acad. Sci. USA, Feb. 1991, pp. 1379-1383, vol. 88, The National Academy of Sciences, Washington, DC.
A.K. Pattnaik et al., “Replication and amplification of defective interfering particle RNAs of vesicular stomatitis virus in cells expressing viral proteins from vectors containing cloned cDNAs”, J. Virol., Jun. 1990, pp. 2948-2957, vol. 64, No. 6, American Society of Microbiology, Washington, DC.
A.M. Arvin, “Measles vaccines—a positive step toward eradicating a negative strand”, Nature Med., Jul. 2000, pp. 744-745, vol. 6, No. 7, Nature America Inc., New York, NY.
Anonymous. Compendium of Animal Rabies Prevention and Control, 2000, National Association of State Public Health Veterinarians, Inc., MMWR, pp. 21-30, vol. 49, No. RR-8.
Anonymous. Rabies Vaccine Failures [editorial], Lancet, Apr. 23, 1988, p. 917, vol. 1, The Lancet Publishing Group, London, UK.
Anzai J. et al., “Identificaiton of a Phosphatase-Sensitive Epitope of Rabies Virus Nucleoprotein which is Recognized by a Monoclonal Antibody 5-22-26,” Microbiology and Immunology, 1997, pp. 229-240, vol. 41, No. 3, Tokyo, Japan.
B. Brochier et al., “Use of recombinant vaccinia-rabies virus for oral vaccination of wildlife against rabies: innocuity to several non-target bait consuming species”, J. Wild!. Dis., 1989, pp. 540-547, vol. 25, Wildlife Disease Association, Lawrence, Kansas.
B. Dietzschold et al., “Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus”, Proc. Natl. Acad. Sci. USA, Jan. 1983, pp. 70-74, vol. 80, No. 1, The National Academy of Sciences, Washington, DC.
B. Dietzschold et al., “Differences in cell-to-cell spread of pathogenic and apathogenic rabies virus in vivo and in vitro”, J. Virol., Oct. 1985, pp. 12-18, vol. 56, No. 1, American Society forMicrobiology, Washington, DC.
B. Dietzschold et at., “Localization and immunological characterization of antigenic domains of rabies virus internal N and NS proteins”, Virus Res., 1987, pp. 103-125, vol. 8, ElsevierScience Publishers B.V., The Netherlands.
B. Perbal, “A Practical Guide to Molecular Cloning”, 1988, John Wiley & Sons, Inc., New York, NY.
B.P. Wilcock et at., “Focal cutaneous vasculitis and alopecia at sites of rabies vaccination in dogs”, J. Am. Vet. Med. Assoc., May 15, 1986, pp. 1174-1177, vol. 188, No. 10, American Veterinary Medical Association, Schaumburg, IL.
C. Mitmoonpitak et al., “Rabies in Thailand”, Epidemiol. Infect., 1998, pp. 165-169, vol. 120, Cambridge University Press, UK.
C.A. Hanlon et al., “First North American field release of a vaccinia-rabies glycoprotein recombinant virus”, J. Wild!. Dis., 1998, pp. 228-239, vol. 34(2), Wildlife Disease Association, Lawrence, Kansas.
C.E. Rupprecht et al., “Oral immunization and protection of raccoons (Procyon /otor) with a vaccinia-rabies glycoprotein recombinant virus vaccine”, Proc. Natl. Acad. Sci. USA, 1986, pp. 7947-7950, vol. 83, The National Academy of Sciences, Washington, DC.
C.E. Rupprecht et al., “Oral wildlife rabies vaccination: development of a recombinant virus vaccine”, Trans. 57th N.A. Wild!. Natl. Res. Conf., 1992, pp. 439-452.
C.E. Rupprecht et al., “The Ascension of Wildlife Rabies: A Cause for Public Health Concern or Intervention?”, Emerging Infect. Dis., Oct.-Dec. 1995, pp. 107-114, vol. 1, No. 4, Centers for Disease Control, Atlanta, Georgia.
C.E. Rupprecht et at., “Human infection due to recombinant vaccinia-rabies glycoprotein virus”, N.
Bingham & McCutchen LLP
Mosher Mary E
University of Georgia Research Foundation Inc.
LandOfFree
Attenuated rabies virus with nucleoprotein mutation at the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Attenuated rabies virus with nucleoprotein mutation at the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Attenuated rabies virus with nucleoprotein mutation at the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4061240